Geisel, Aeras to Collaborate on Study of New TB Vaccine


Read the full story, published by the Geisel School of Medicine.

The Geisel School of Medicine and Aeras, a global nonprofit biotech organization, have announced a collaboration to jointly conduct a trial of a new vaccine against tuberculosis (TB), one of the world’s deadliest diseases.

The DAR-901 scientific team members at the Geisel School of Medicine are, from left, Brenda Haynes, Lisa Adams, Tim Lahey, Wendy Wieland-Alter, Richard Waddell, Ford von Reyn, and Ruth Connor. (Photo by Lars Blackmore)

The vaccine, known as DAR-901, is related to the vaccine SRL-172, previously shown by Dartmouth investigators to decrease the risk of TB in a trial known as the DarDar Trial.

In the March 19 announcement, Aeras indicated that DAR-901 would now be added to Aeras’s portfolio of TB vaccines in clinical development. "The world desperately needs new vaccines to prevent the global spread of TB. We are pleased to join forces with Dartmouth’s Dr. Ford von Reyn and the DAR-901 partners in manufacturing the candidate and supporting the first clinical trial,” said Aeras President and CEO Tom Evans.

Office of Communications